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Abstract 
Rationale & aim: Various types of cell therapies are currently under investigation for the treatment of 
ischemic stroke patients. To bridge the gap between cell administration and therapeutic outcome, there is a 
need for non-invasive monitoring of these innovative therapeutic approaches. Spectral photon counting 
computed tomography (SPCCT) is a new imaging modality that may be suitable for cell tracking. SPCCT is the 
next generation of clinical CT that allows the selective visualization and quantification of multiple contrast 
agents. The aims of this study are: (i) to demonstrate the feasibility of using SPCCT to longitudinally monitor 
and quantify therapeutic cells, i.e. bone marrow-derived M2-polarized macrophages transplanted in rats with 
brain damage; and (ii) to evaluate the potential of this approach to discriminate M2-polarized macrophages 
from their encapsulating scaffold. 
Methods: Twenty one rats received an intralesional transplantation of bone marrow-derived M2-polarized 
macrophages. In the first set of experiments, cells were labeled with gold nanoparticles and tracked for up to 
two weeks post-injection in a monocolor study via gold K-edge imaging. In the second set of experiments, the 
same protocol was repeated for a bicolor study, in which the labeled cells are embedded in iodine 
nanoparticle-labeled scaffold. The amount of gold in the brain was longitudinally quantified using gold K-edge 
images reconstructed from SPCCT acquisition. Animals were sacrificed at different time points post-injection, 
and ICP-OES was used to validate the accuracy of gold quantification from SPCCT imaging.  
Results: The feasibility of therapeutic cell tracking was successfully demonstrated in brain-damaged rats with 
SPCCT imaging. The imaging modality enabled cell monitoring for up to 2 weeks post-injection, in a specific and 
quantitative manner. Differentiation of labeled cells and their embedding scaffold was also feasible with SPCCT 
imaging, with a detection limit as low as 5,000 cells in a voxel of 250 × 250 × 250 µm in dimension in vivo.   
Conclusion: Multicolor SPCCT is an innovative translational imaging tool that allows monitoring and 
quantification of therapeutic cells and their encapsulating scaffold transplanted in the damaged rat brain. 
Key words: multicolor spectral photon-counting CT, regenerative medicine, cell therapy, cell tracking, neurology 
Introduction 
Stroke is the leading cause of long-term 
disability with no effective cure after the first hours of 
onset. Various types of cell therapies are currently 
being evaluated in many clinical trials involving 
patients with ischemic stroke (1). A meta-analysis of 








administration is associated with the best treatment 
efficacy compared to other administration routes, as 
they can thus act locally by secreting neurotrophic 
factors for example (2-4). Recently, two independent 
clinical trials reported the safety of intracerebral 
administration of different types of therapeutic cells 
in stroke patients (5, 6). The infarct cavity allows the 
injection of a large volume of cells; however, it is a 
hostile environment for cell engraftment. To improve 
the integration of the grafted cells, these cells can be 
embedded within a bioengineered scaffold (7). To 
bridge the gap between the administration of 
regenerative therapy and the clinical trial outcome, 
the regulatory agencies that approve 
advanced-therapy medicinal products (ATMPs) have 
highlighted the need for non-invasive imaging tools 
(8). The challenge is to propose a solution that 
involves clinically relevant imaging techniques, in 
order to foster the clinical translation of these 
innovative theranostic approaches. 
In human trials of cell tracking, nuclear medicine 
imaging, such as positron emission tomography (PET) 
and single photon emission computed tomography 
(SPECT), is mainly used (9). However, the relatively 
short half-lives of radiotracers prevent the long-term 
tracking of administrated cells. Gene reporter imaging 
with PET or SPECT may overcome this problem (10), 
although to date these technologies remain costly and 
not widely available. Magnetic resonance imaging 
(MRI) and X-ray computed tomography (CT) are the 
leading three-dimensional (3D) radiological 
technologies around the world. Coupled with contrast 
agents, both modalities are regarded as the imaging 
techniques that can potentially track administered 
cells up to several weeks. To render cells detectable, a 
contrast agent is incorporated into cells prior to 
transplantation. Superparamagnetic particles of iron 
oxide (SPIO) and gold nanoparticles (AuNPs) are 
examples of widely studied contrast agents for MRI 
and CT, respectively (11, 12). One limitation of both 
these approaches is the lack of specificity of the signal 
produced by the labeled cells, which makes it difficult 
to non-equivocally distinguish the signal of labeled 
cells from other sources of hyperdensities 
(microhemorrhages or calcifications for instance). A 
recent breakthrough in CT technology has been the 
introduction of dual-energy CT (DECT) into clinical 
CT scanners. DECT has several advantages compared 
to conventional CT, including better contrast-to-noise 
ratio and fewer artifacts (13). Importantly, after the 
administration of an iodinated contrast agent, DECT 
allows the reconstruction of non-contrast and 
contrast-enhanced images based on a single 
acquisition, eliminating the need for pre-scan. This 
leads to X-ray dose reduction without altering the 
diagnostic value. The development of spectral 
photon-counting detectors rather than 
energy-integrating detectors has extended the DECT 
approach to a multispectral approach. This next 
generation spectral photon counting CT (SPCCT) is 
expected to further expand the boundaries of spectral 
CT in terms of noise reduction and tissue 
differentiation (14). It also improves the intrinsic 
spatial resolution owing to small pixel detector size 
(~250 µm) (15, 16). In addition, SPCCT allows 
selective visualization and quantification of multiple 
contrast agents by exploiting the K-edge discontinuity 
in X-ray absorption, a concept coined ‘K-edge 
imaging’ or ‘multicolor CT’ (17). The first reports of 
bicolor imaging with SPCCT have demonstrated the 
potential of this innovative approach (18-23), with 
many future applications yet to be developed. 
This study aims to: (i) demonstrate the feasibility 
of using SPCCT to longitudinally monitor and 
quantify AuNP-labeled therapeutic cells transplanted 
into brain-damaged rats; and (ii) evaluate the 
potential of this approach to discriminate the labeled 
cells from their encapsulating scaffold, both labeled 
with different types of contrast agents. Bone 
marrow-derived M2-polarized (repair) macrophages 
were used as the therapeutic cells (24, 25). The 
commercially-available scaffold PuraMatrix® was 
employed to encapsulate the cells (26, 27). Stereotaxic 
injection into rodent brains was chosen as a mean to 
model intracerebral administration in humans. A 
SPCCT prototype system (Philips Healthcare, Haifa, 
Israel) with small field of view (16.8 cm) was used for 
image acquisition (28). This system has five thresholds 
that could be adjusted in order to allow photon 
energy-based discrimination of any given element 
that has a K-edge in the range of 30 – 120 keV.    
Materials and Methods 
Animals 
All experimental procedures involving animals 
and their care were carried out in accordance with the 
European regulation for animal use (APAFIS 
agreement number #4688). This study was approved 
by the local ethics committee of our institution (C2EA 
– 42, local ethic board). Adult male Sprague-Dawley 
rats (Janvier, France) that were 6 to 7 weeks-old at 
reception and with a body weight in the range of 
250-300 g and C57Bl/6 mice (Janvier, France) that 
were 5 weeks-old at reception and with a body weight 
in the range of 25-30 g were used. An acclimation 
period of at least 7 days was respected. Animals were 
housed in a temperature- and humidity-controlled 
environment (21 ± 3 °C), on 12:12 h light-dark cycle, 
having free access to standard chow and tap water. 




Housing Pexiglas cages were bedded with wood dust 
and enriched with tunnels and wood sticks (rats) or 
domes (mice). The data are reported according to the 
ARRIVE guidelines (Animal Research: Reporting of In 
vivo Experiments). 
Contrast agents 
Gold nanoparticles (AuNPs) 
11-Mercaptoundecanoic acid capped gold 
nanoparticles (11-MUDA AuNPs) were synthesized 
via a previously reported adaptation of the Turkevich 
method (29, 30). In brief, 85 mg of gold (III) chloride 
salt was dissolved in 500 ml of ultrapure water and 
brought to a boil while stirring. 25 mL of sodium 
citrate (38.8 mM) was added and the solution allowed 
to boil for additional 15 minutes before cooling to 
room temperature. A wine-red solution of gold 
nanoparticles resulted from this procedure. To cap the 
gold nanoparticles, 2.6 mg of 11-MUDA dissolved in 1 
mL of ethanol was added, and the solution was stirred 
overnight. The resulting 11-MUDA AuNPs were 
purified by centrifuging them three times at 8.5 krcf 
and exchanging the supernatant with ultrapure water 
each time. AuNPs were then sterilized via syringe 
filtration (size: 0.45 µm) before further use. These 
nanoparticles had the following characteristics: peak 
absorbance of 524 nm, average hydrodynamic 
diameter of 22 nm with PDI of 0.2, core size of  11 ± 1 
nm, and zeta potential of -44.4 mV. 
Iodinated nanoparticles (INPs) 
Concentrated aqueous suspensions of INPs were 
prepared in two steps of emulsification and 
concentration as follows (31). The iodinated polymer 
TIB-PVAL was a 2,3,5-triodobenzoyl ester of 
poly(vinyl alcohol) containing 70 wt% of iodine. The 
emulsification of TIB-PVAL in water was performed 
by mixing 25 mL of 4 wt% TIB-PVAL in THF and 
50 mL of deionized water. A block copolymer 
polycaprolactone-block-poly(ethylene glycol) was 
used as an emulsifier. After evaporation of THF under 
reduced pressure, the resulting aqueous suspension 
of INPs had a concentration of 15 mg iodine/mL. As 
the second step, the iodine concentration was 
increased up to 100 mg(I)/mL by means of 
centrifugation and redispersion of the pellet into a 
small volume of water. INPs had the following 
characteristics: peak absorbance of 237 nm, 
hydrodynamic diameter of 122 nm with PDI of 0.2, 
and core size of 100 ± 15 nm. 
Cell culture and cell labeling  
Bone marrow cells were harvested by flushing 
out tibias and femurs of donor animals. Total bone 
marrow cells were seeded on uncoated 6-well plates 
at 5×105 cells/mL in RPMI 1640 with Glutamax 
(Fisher Scientific, Illkirch, France) supplemented with 
10% fetal calf serum (SVF premium, Dutscher, 
France), 1% penicillin-streptomycin Fisher Scientific, 
Illkirch, France) and 25 ng/mL of mouse 
macrophage-colony stimulating factor (mM-CSF) 
(Miltenyi Biotec, Paris, France). The cell cultures were 
incubated at 37 °C in humidified 5% CO2. Seven days 
after plating, non-adherent cells were harvested and 
adherent cells were washed twice in 
phosphate-buffered saline (PBS). The harvested bone 
marrow-derived macrophages were then stimulated 
with interleukin-4 (20 ng/mL) (Miltenyi Biotec, Paris, 
France) for 48 h to generate M2 alternatively-activated 
macrophages. Macrophage cell culture purity under 
these experimental conditions was repeatedly found 
to exceed 95% on flow cytometry analysis of CD11b+ 
cells (data not shown). At day 6, cells were incubated 
with AuNPs at 0.1 mg/mL for 18 h, based on a 
protocol that provided high AuNPs uptake while 
maintaining cell viability (29). Immediately after 
labeling, cells were detached by trypsination, washed 
once in PBS, counted and resuspended in Ca2+-Mg2+ 
sterile PBS for in vivo injection. AuNP internalization 
and cell morphology post-labeling were assessed by 
light microscopy. The viability of the AuNP labeled 
cells was examined using the LIVE/DEAD assay 
(Invitrogen, Carlsbad, CA, USA). The efficiency of 
labeling was determined based on inductively 
coupled plasma-optical emission spectrometry 
(ICP-OES) using three different bone-marrows and 
triplicates for each bone-marrow.  
Scaffold and scaffold labeling 
Puramatrix (3-D Matrix, MA, USA) is a synthetic 
peptide that undergoes self-assembly into nanofiber 
hydrogels similar to the extracellular matrix upon 
introduction of monovalent cations in physiological 
conditions. PuraMatrix thus provides a suitable 
biological scaffold for cell transplantation, and it has 
been used for central nervous system regeneration 
(27, 32). For injection of AuNPs-labeled cells in 
INPs-labeled scaffold, the total volume of injectable 
solution (10 µL) was composed of PuraMatrix (1/4 of 
10 µL), INPs solution (1/8 of 10 µL) and 
AuNPs-labeled cells in PBS (remaining volume).   
In vitro studies 
The accuracy of quantification in SPCCT 
material imaging has been demonstrated previously 
by phantom imaging of iodine, gold and their mixture 
with other contrast agents (17). In this study, thirteen 
samples were prepared by suspending the gold or 
iodine nanoparticles in 1% agarose gel placed in 
Eppendorf tubes with a range of concentrations: 0, 10, 




15, 20, 30, 40 and 60 mM for INPs and 0, 10, 15, 20, 30, 
and 40 mM for AuNPs (thus resulting in the same 
range of 0 – 8 mg/mL for each material). These 
phantoms were scanned at each imaging time point 
for calibration purpose in longitudinal in vivo studies 
(see below). In addition, to evaluate the performance 
of SPCCT quantification in our experimental setting, 
labeled cells pellets were prepared in the same 
conditions as for the in vivo administration, i.e. 10 µL 
of PBS with decreasing quantity of cells: 1 x 106, 0.5 x 
106, 0.25 x 106, 0.125 x 106 and no cells, placed at the 
bottom of Eppendorf tubes and secured with 1% 
agarose gel on top.  
In vivo studies 
Overall protocol 
Figure 1 shows the experimental design of in vivo 
studies. In order to generate a lesion cavity that 
mimics stroke infarct at the chronic stage, 21 rats 
(experimental units) received an intracerebral 
injection of lipopolysaccharide (LPS) (33). To evaluate 
the exact lesion location for cell administration, rat 
brains were imaged 2 weeks later by T2-weighted 
MRI. Subsequently, the rats received an intra-lesional 
injection of different therapeutic materials (e.g. cells ± 
scaffold) as detailed thereafter. For this set of 
experiments, rats were randomly assigned to injection 
with or without scaffold. In the first set of 
experiments, cells were labeled with gold 
nanoparticles (AuNPs) and tracked up to two weeks 
post-injection using K-edge imaging of gold 
(monocolor study, n=13 LPS-treated rats). For the 
second set of experiments, the same protocol was 
repeated for a bicolor study, in which the labeled cells 
are embedded in iodine nanoparticle (INP)-labeled 
scaffold (bicolor study, n=8 LPS-treated rats). In both 
cases, the success of transplantation was determined 
by performing µCT immediately after intracerebral 
cell administration. The µCT images are also shown as 
images of reference for accurate cell location. Sample 
size was determined in order to obtain enough data 
for this proof-of-concept study.  
Animal models and cell transplantation 
Animals were anesthetized by breathing 3-4% 
isoflurane (ISO-VET, Piramal Healthcare, Morpeth, 
UK) in air and maintained under 1.5% isoflurane in 
air using a face mask and mounted in a stereotaxic 
apparatus (D. Kopf Instruments). Isoflurane 
anesthesia was selected since it allows modulating 
anesthesia depth. Rectal temperature was kept at 37 ± 
1 °C throughout the surgical procedures, using a 
feedback-regulated heating pad. To alleviate pain, 
buprenorphine was administered subcutaneously at 
the dose of 0.05 mg/kg prior to the surgery. Lubricant 
ophthalmic gel was applied on both eyes to prevent 
ocular dehydration, and the surgical site was shaved 
and disinfected with antiseptic solution (i.e. 10 % 
iodopovidone). To mimic stroke infarct, rats were 
stereotaxically injected with 50 µg of LPS from 
Escherichia coli (Sigma-Aldrich, Saint-Louis, USA) 
dissolved in 4 µL saline in the right hemisphere of the 
brain (0.5 mm anterior to bregma, 3.0 mm in lateral 
direction, 2 µL at 5.5 mm and 2 µL at 4.5 mm deep 
from the cortical surface). In addition, one mouse was 
submitted to ischemic stroke by permanent middle 
cerebral artery occlusion (pMCAO) according to a 
protocol published elsewhere (34). Briefly, the right 
distal middle cerebral artery was exposed by 
subtemporal craniotomy and occluded by 
electrocoagulation. AuNP-labeled cells (in the range 
of 0.125 x 106 to 0.5 x 106) were intracerebrally 
transplanted in 10 µL vehicle (PBS or scaffold) inside 
the lesion, using stereotaxic coordinates based on 
 
 
Figure 1. Experimental timeline for longitudinal multimodal imaging of brain-damaged rats transplanted with cell therapy. AuNPs: gold 
nanoparticles; ICP-OES: inductively coupled plasma-optical emission spectrometry; INPs: iodinated nanoparticles; LPS: lipopolysaccharide; µCT: micro-computed 
tomography; MRI: magnetic resonance imaging; pMCAO: permanent middle cerebral artery occlusion; SPCCT: spectral photon counting computed tomography. 




pre-surgery MRI for each animal. At the end of the 
surgery, the wounds were cleaned with sterile saline 
solution, disinfected, and covered with lidocaine. 
Animals were allowed to completely wake up from 
anesthesia under a heating lamp and then housed 
individually for approximately 24 hours after the 
surgery. The surgical wound appearance was visually 
checked for correct healing. 
Monocolor study 
Thirteen LPS-treated rats were intracerebrally 
administered with 0.5 x 106 AuNP-labeled cells 
encapsulated either in PBS (n=6) or in scaffold (n=7). 
These rats were imaged with SPCCT three times 
during the first 2 weeks of post-transplantation period 
- once in the first half of the first week (Day 0-3), once 
in the second half of the first week (Day 4-7), and once 
at the end of the second week (Day 13-14). Subgroups 
of rats were sacrificed at each time point to compare 
the gold content estimated with SPCCT analysis with 
the gold content measured by ICP-OES (n=2 at Day 
0-3, n=7 at Day 4-7 and n=4 at Day 13-14).  
Bicolor study 
To evaluate the feasibility of bicolor imaging, 
two LPS-treated rats and one pMCAO mouse were 
intracerebrally administered with 0.5 x 106 cells 
encapsulated in 10 µL iodine-labeled scaffold and 
then imaged twice during the first week of 
post-administration (once in Day 1-2 and once in Day 
4-6). Lastly, to evaluate the limits of detection for 
AuNP-labeled cells in the context of bicolor imaging, 
6 rats received a range of cell quantities, i.e. 0.5 x 106 
(n=2), 0.25 x 106 (n=2) or 0.125 x 106 (n=2). The iodine 
quantity in the scaffold did not vary between groups. 
These rats were imaged twice during the first week (at 
Day 1-2 and Day 4-6) and once at the end of the 
second week (Day 12-14).  
In vivo multimodal imaging  
All imaging procedures were performed under 
1-2% isoflurane anesthesia. System characteristics and 
acquisition parameters for MRI, µCT, CT and SPCCT 
are presented in Table 1. The SPCCT scanner is 
described in details in previous studies (17, 28). In 
brief, it is based on a clinical iCT platform (Philips 
Healthcare, Haifa, Israel), operating with a standard 
X-ray source and energy-resolving photon counting 
detectors made of cadmium-zinc telluride, with 5 
energy thresholds that can be tuned according to the 
materials of interest. Tube voltages can be set to 80, 
100 or 120 kVp and tube currents from 10 to 100 mA. 
The effective z-collimation is 2.5 mm in the isocenter, 
in-plane field of view is 168 mm, Z-coverage is 2 mm 
and minimum rotation time is 0.75 sec/rotation. We 
acquired images using both axial and helical 
acquisition modes at a tube current of 100 mA and a 
tube voltage of 120 kVp with the energy thresholds of 
30, 53, 78, 83 and 98 keV. For reconstruction, the 
image chain used a two-step material decomposition 
approach that first generates material specific 
sinograms for each material of interest (e.g. gold, 
iodine, gadolinium, water), which is followed by 
reconstruction of each sinogram into specific material 
image, depending on the user’s choice. Taken 
together, the specific images are generated by best fit 
of the measured count rates in the five energy bins 
available to calibration data from phantom imaging. 
A maximum-likelihood based material decomposition 
(35) based on literature data of the attenuations (36) of 
the target materials was applied to derive material 
sinograms. Further details are provided in previous 
studies (17, 22). 
 
Table 1. System characteristics and acquisition parameters for each imaging modality. 
 Computed tomography (CT) 
 µCT CT SPCCT 
System Siemens INVEON GE Brightspeed Philips prototype 
Tension (kVp) 80 120 120 
Current (mA) 500 150 100 
In-plane resolution (µm) 56 310 250 
Slice thickness (µm) 56 625 250 
Energy thresholds (keV) N/A N/A 30, 53, 78, 83, 98 
Acquisition time (sec) 792 3 17 
 Magnetic resonance imaging (MRI) 
System Bruker Avance II Sequence T2 - RARE factor 8 
Field strength 7T TE/TR (ms/ms) 57.7/5000 ms 
Gradients 440 mT/m In-plane resolution (µm) 117 
Software ParaVision 5.1 Slice thickness (µm) 800 
Coils diameters (mm) 15 / 25 Acquisition time (min) 4 
µCT: micro-computed tomography; RARE: rapid acquisition with relaxation enhancement; SPCCT: spectral photon counting computed tomography; TE: echo time; TR: 
repetition time. 
 





Image analysis was performed using ImageJ 
software (National Institute of Health, USA, 
imagej.nih.gox/ij/). The gold concentration in 
mg/mL was quantified by measuring the signal 
intensity on gold K-edge images in the regions of 
interests (ROI). In order to compare the quantitative 
performances of SPCCT scans with ICP-OES (which 
provides the gold mass measured in the sample in 
µg), the gold content was estimated by multiplying 
the concentration by the ROI volume.  
Inductively coupled plasma-optical emission 
spectrometry (ICP-OES) 
Animals were sacrificed at the end of the 
experiment, and their brains were sampled for 
ICP-OES analysis of gold content, according to a 
protocol published elsewhere (37). In brief, the 
harvested brain samples were homogenized before 
being digested in 1 mL of nitric acid at 75 °C for 24 
hours. The samples were further digested for another 
3 hours at 60 °C after addition of 300 µL of 
hydrochloric acid.  5 mL of deionized water was then 
added to 1 mL of the digested sample solution for 
ICP-OES analysis. 
Statistics 
Data are presented as mean ± standard 
deviation. Linear regression was used to correlate 
gold content estimated by SPCCT analysis with that 
measured by ICP-OES. The agreement between gold 
content estimated by SPCCT analysis and by ICP-OES 
was assessed with Bland-Altman analysis.  
Results 
For the purpose of illustration, Figure S1 shows 
the principle of bicolor imaging with SPCCT using a 
healthy rat that was intracerebrally injected with 
AuNP-labeled cells on one side and with gadolinium 
nanoparticles (GdNP)-labeled scaffold on the other 
side. The contrast agents could not be differentiated 
on conventional images, while gold K-edge images 
were able to detect AuNP-labeled cells in a 
non-equivocal manner. These GdNP were used in 
another SPCCT project of our 
consortium; (38) however, we decided 
to use iodinated nanoparticles instead 
for this study because of the artifacts 
GdNP produce in MRI (Figure S1E). 
In vitro studies 
Bone-marrow derived M2- 
polarized macrophages efficiently 
ingested AuNPs without any noticeable 
change in morphology compared to 
non-labeled cells in control group 
(Figure 1). AuNP uptake was 
confirmed by ICP-OES, with an average 
gold load per cell of 128 ± 34 pg. The 
cell viability was 86 ± 1% in the control 
group and 77 ± 3% after labeling with 
AuNPs. In other words, the cell 
viability of AuNP-labeled cells was 89% 
of the non-labeled cells. Both 
conventional and gold K-edge images 
of cell pellets showed an observable 
increase in attenuation that was 
dependent on the number of cells in the 
pellets (Figure 2). The mean volume 
occupied by the cells in vitro was 2.8 ± 
1.9 µL. There was a strong linear 
relationship between the gold content 
measured on gold K-edge images by 
SPCCT analysis and that measured by 
ICP-OES in each cell pellet (R2=0.99). 
Gold content from K-edge images was 
slightly underestimated when 
 
 
Figure 2. Pellets of AuNP-labeled macrophages at decreasing cell number imaged with a 
single SPCCT acquisition. (A) conventional image; (B) water image; (C) gold K-edge image; (D) 
overlay of gold K-edge image and water image; (E) Linear relationship between the gold content 
estimated by SPCCT on gold K-edge image and that measured by ICP-OES in each tube. From left to 
right: 1 x 106, 0.5 x 106, 0.25 x 106, 0.125 x 106 and no cells. Color bars indicate Hounsfield units for 
conventional images and concentration in mg/mL for material images. CT: computed tomography; 
ICP-OES: inductively coupled plasma-optical emission spectrometry; SPCCT: spectral 
photon-counting computed tomography. 




compared to the measurement from ICP-OES (slope 
of 0.9). 
In vivo studies 
Monocolor study 
The conventional images reconstructed from 
SPCCT acquisition had significantly better resolution 
than the CT images acquired from a (conventional) 
clinical scanner (Figure S2). Gold K-edge images 
allowed a longitudinal monitoring of the brain 
distribution of AuNP-labeled macrophages in a 
non-equivocal manner (Figure 3).  
One animal from the PBS group was 
inadvertently injected into the lateral ventricle and 
was therefore excluded from the quantitative analysis. 
This injection failure was clearly depicted by SPCCT 
despite cell dispersion (Figure S3). Thus 12/13 
animals were included in the analysis (PBS: n=5, 
scaffold: n=7). Moreover, one rat did not get SPCCT 
data at Day 14 for technical reasons. Quantitative 
analysis of gold content from SPCCT images revealed 
a heterogeneity in the gold content that was present 
into the brain of each rat at the first scanning time 
point (i.e. Day 0-3 post-injection) (Figure 4A-B). In 
particular, one of the rats had a very low gold signal 
and cell volume (1.0 µg in 0.5 µL) (Figure 4B, dashed 
line), possibly due to suboptimal cell administration. 
The gold content remained relatively stable over time 
in both groups that had cells delivered in PBS (Figure 
4A) and in scaffold (Figure 4B). The mean volume 
occupied by the cells in vivo was 2.7 ± 1.0 µL. At the 
end of the experiment, the average gold content in the 
brain measured by ICP-OES was 48 ± 18 µg (N=12). In 
comparison, SPCCT analysis provided an average 
value of 44 ± 23 µg in the last in vivo imaging time 
point for the same 12 animals. The animal with very 
low gold signal had only 7.4 µg of gold in its brain as 
measured by ICP-OES; thus confirming the injection 
problem that had been detected with SPCCT.     
Figure 4C shows the Bland-Altman plot 
describing the agreement between the gold content 
estimated by SPCCT analysis and that measured by 
ICP-OES. In average, gold K-edge images 
underestimated gold content by 5 µg (bias of 10%) 
with 95% limits of agreement of [-29; +19] µg. One 
animal with high gold value appeared to be an outlier 
(i.e. outside the limits of agreement). When excluding 
this animal from linear correlation analysis, the same 
relationship from the in vitro study was found 
between gold content from SPCCT analysis and from 
ICP-OES (Figure 4D, R2 = 0.80, slope of 0.9). 
Bicolor study  
Conventional images did not allow the 
differentiation of AuNP-labeled cells from 
INP-labeled scaffold, while material images provided 
different gold and iodine locations, corresponding to 
the respective locations of cells and scaffold (Figure 5). 
As previously reported (28), there was some cross-talk 
between iodine and calcium, which resulted in 
appearance of the skull in the iodine image. As for 
monocolor imaging, bicolor imaging of gold and 
iodine allowed monitoring labeled cells and scaffold 
in the brain brain up to 2 weeks post-transplantation 
(Figure S4). Cells and scaffold monitoring was also 




Figure 3. Longitudinal SPCCT imaging of a brain-damaged rat 1 day (A-C) and 7 days (D-F) post-transplantation of 0.5 x 106 AuNPs-labeled 
macrophages. (A) & (D) conventional image; (B) & (E) water image; (C) & (F) gold K-edge image; (G) corresponding µCT obtained on the day of injection; (H) 
overlay between baseline MRI (note the striatal lesion that appears as a hyperintense signal on T2-weighted imaging), conventional and gold K-edge images. Color bars 
indicate Hounsfield units for conventional images and concentration in mg/mL for material images. µCT: micro-computed tomography; MRI: magnetic resonance 
imaging; SPCCT: spectral photon counting computed tomography. 





Figure 4. Monocolor study: quantitative analysis. (A) Graph plotting the average gold content estimated on gold K-edge images over time in the group of rats 
that received cells in PBS; (B) Graph plotting the average gold content estimated by SPCCT on gold K-edge images over time in the group of rats that received cells 
in scaffold; (C) Bland–Altman plot of gold content estimated by SPCCT on gold K-edge images and that measured by ICP-OES for each brain for the 2 groups; (D) 
Linear analysis of the same data; the red square represents an outlier that was excluded from linear regression. Grey lines represent individual animals and orange 
lines represent the mean ± standard deviation. Dotted line of graph B represents one animal that was excluded from analysis because of administration failure. 
ICP-OES: inductively coupled plasma-optical emission spectrometry; PBS: phosphate-buffered saline; SPCCT: spectral photon counting computed tomography. 
 
Figure 5. Longitudinal SPCCT imaging of a brain-damaged rat 1 day (A-D) and 4 days (F-I) post-transplantation of 0.5 x 106AuNPs-labeled 
macrophages embedded in INP-labeled scaffold. (A) & (E) conventional image; (B) & (F) water image; (C) & (G) gold K-edge image; (D) & (H) iodine image. 
Color bars indicate Hounsfield units for conventional images and concentration in mg/mL for material images. SPCCT: spectral photon counting computed 
tomography; MRI: magnetic resonance imaging. 
 
One animal died at Day 12 and was imaged 
ex-vivo for the last imaging point. All animals were 
included in quantitative analysis (n=9). The mean 
volume occupied by both cells and scaffold was 4.9 ± 
1.8 µL. In agreement with the monocolor study, the 
gold content that was present in the brain of each rat 
at the first scanning time point (i.e. Day 1-2 
post-injection) was heterogeneous across animals and 
remained stable afterwards (Figure 6). The mean 
volume occupied by cells on gold K-edge images was 
1.4 ± 0.3 µL. ICP-OES provided a value of 59 ± 8 µg of 
gold in the brain of rats sacrificed at Day 4 of 
post-transplantation (injected with 0.5 x 106 cells), 
compared to 72 ± 4 µg estimated by SPCCT analysis at 
the same time point. The decrease in gold content 
estimated by SPCCT in each group paralleled the 




decrease in injected cell quantity in each group 
(Figure 6). The limit of detection was 4902 ± 964 
AuNP-labeled cells per voxel. 
Discussion 
In this study, we have shown that therapeutic 
cell tracking was feasible in brain-damaged rats with 
SPCCT. This technique enabled cell monitoring for up 
to 2 weeks post-injection, in a specific and 
quantitative manner, with a detection limit as low as 
5,000 cells in a voxel of 250 × 250 × 250 µm in vivo. 
Furthermore, we have provided the proof-of-concept 
that simultaneous imaging with discrimination of 
cells and their embedding scaffold was feasible with 
SPCCT, thus paving the way for monitoring ATMPs 
combinations in the long term with the 
next-generation multicolor clinical SPCCT scanners.  
MRI coupled with cell labeling with SPIO has 
been extensively used to track cells in several clinical 
applications including ischemic stroke (11). One major 
limitation of SPIO-enhanced MRI, however, is that 
iron oxide labeling suppresses MR signal and thus 
hampers the evaluation of therapeutic cells’ effect on 
tissue regeneration by other MRI sequences. Another 
limitation is that cell quantification is very difficult 
with SPIOs. This led us to seek an alternative imaging 
modality, with the pre-requisite to preserve MRI 
contrast and allow the quantitative monitoring of cells 
over time. One possibility is to use perfluorocarbon 
contrast agents to label the cells and to image them 
with 19F MRI (39, 40). CT represents another attractive 
translational option, as it is widely available and 
intrinsically quantitative, while some radiopaque 
elements such as iodine and gold do not affect MR 
signals. Tracking therapeutic cells with CT is an 
emerging field (reviewed in (12)). The main 
originality of spectral CT compared to other 
non-spectral X-ray-based approaches (µCT, clinical 
CT or synchrotron radiation CT (41)) is represented by 
its specificity with regard to the detection of gold or 
other elements with K-edge energies in the 
appropriate range (~40 – 100 keV) (42-44). Pioneering 
work for the specific imaging of macrophages with 
SPCCT was published 10 years ago in a mouse model 
of atherosclerosis (45). However, the technology was 
not yet mature and the image acquisition took several 
hours, which prevented in vivo applications, until the 
development of novel SPCCT prototypes such as the 
one used in the current study.  
Using a specific imaging approach has many 
advantages. First, it simplifies both data acquisition 
and post-processing, which is a major asset for clinical 
translation at the diagnostic, organizational and 
financial levels. Second, it allows the exclusion of 
confounding signals from endogenous origin due, for 
instance, to recent hemorrhage (which is the most 
common complication of ischemic stroke), intracranial 
calcifications (which may be found in patients 
especially when they are aged (46)) or bone (i.e. the 
skull for cerebral imaging). Third, it allows 
differentiation of contrast agents of interest from other 
contrast agents. For example, iodine may be 
administered intravenously or intraarterially for 
diagnostic or interventional purposes and accumulate 
into the brain parenchyma as a result of blood brain 
barrier disruption. Alternatively, in the present study, 
we took advantage of this unique feature to track both 
cells and the cell-embedding scaffold. The capacity to 
discriminate two distinct contrast agents at the same 
location was limited to optical imaging techniques 
thus far. To the best of our knowledge, this is the first 
time that both therapeutic cells and scaffold may be 
tracked simultaneously in 3D and in a non-ambiguous 
manner using a medical imaging technique. This 
represents a technological leap and a great promise 
for evaluating ATMPs combination, for which fate 
and elimination rate should be evaluated 
independently. In this paper, our aim was to 
demonstrate that bicolor imaging with SPCCT can 
allow differentiation of therapeutic cells from their 
 
 
Figure 6. Bicolor study: quantitative analysis. Graph plotting the average gold content estimated on gold K-edge images over time in the group of rats that 
received (A) 0.5 x 106; (B) 0.25 x 106; and (C) 0.125 x 106 cells in INP-labeled scaffold. Grey lines represent individual animals (dotted lines: 1 week follow-up and plain 
lines: 2 weeks follow-up); blue, respectively orange, lines represent the mean ± standard deviation of animals with 1 week, respectively 2 weeks, follow-up. SPCCT: 
spectral photon counting computed tomography. 




encapsulating scaffold, both labeled with distinct 
contrast agents. We have chosen to use gold for cell 
labeling and iodine for scaffold labeling in order to 
minimize the cross-talk that may arise from elements 
with closer K-edges, such as gold and gadolinium, 
based on previously published phantom and animal 
studies (17, 19, 20). 
One key feature of using imaging in the context 
of restorative therapy is the possibility to monitor the 
success of cell transplantation. The variability in 
clinical outcome is still a clear obstacle for the 
adoption of cell therapies (47); however, it is crucial to 
determine if patients are non-responders due to a lack 
of treatment efficacy or to the failure of cell 
transplantation procedure and/or a suboptimal 
administration of cells. Another advantage of SPCCT 
is the fact that it is quantitative, thus allowing 
estimating the number of cells present in the sample. 
SPCCT provided an evaluation of gold amount that 
was in good agreement with that of ICP-OES taken as 
gold standard. This confirms and extends the 
quantitative performances previously obtained with 
different contrast agents using the same SPCCT 
prototype (17, 19, 38, 48). Our study demonstrates that 
there is an important variability in the number of 
transplanted cells from one animal to another, even in 
the highly controlled lab environment. One animal 
was excluded from the study because cells were 
injected in the lateral ventricle (which undergoes 
dilatation in the presence of focal cerebral injury), and 
one animal would have been excluded from the 
analysis because of the very low number of grafted 
cells. In the remaining animals, there was still a 
disparity at the baseline that could be accounted for in 
a therapeutic trial through a multivariate analysis. 
The use of SPCCT imaging coupled to cell labeling 
with AuNPs may thus allow a more rigorous 
inclusion of animals/patients and a more reliable 
statistical analysis of data in future preclinical and 
clinical trials of cell therapy. In case of intracerebral 
injection, using a technique that can specifically image 
AuNPs-labeled cells ascertains that other sources of 
hyperdensities, such as microhemorrhages caused by 
the injection procedure, are not mistakenly taken for 
therapeutic cells. These aspects taken together 
translate into a reduction of animals required for 
obtaining robust results in preclinical trials. 
The other interest of using SPCCT imaging is in 
the possibility to depict the 3D cell distribution within 
the whole brain and to monitor their fate over a long 
period of time. This is essential to assess cell 
engraftment and to evaluate whether an early 
disappearance of cells might explain a lack of 
therapeutic efficacy. In our study, we observed very 
little changes in cell deployment after their injection in 
the brain, whether they were administered in buffer 
solution or embedded in a scaffold. The amount of 
gold that was estimated using K-edge gold imaging 
with SPCCT did not vary over time for a given 
individual. This might suggest that the number of 
transplanted cells remained relatively constant and 
that cells did not proliferate (as expected in case of 
macrophages). Of course, one limitation of the 
approach is that it does not allow determining 
whether cells are still labeled with AuNPs or, if this is 
the case, whether they are still viable and functional. 
However, this is true for any form of cell labeling with 
NPs (i.e. comparable approaches such as 
SPIO-enhanced or 19F MRI) (40, 49). Indeed, AuNPs 
may be released from cells and taken up by nearby 
endogenous macrophages. We were not able to 
evaluate this hypothesis in our study because we used 
repair macrophages as therapeutic cells. We have 
chosen these cells both because they represent 
promising candidates to treat ischemic stroke patients 
(24, 25) and because they are easy to label with NPs 
due to their phagocytic capacities (50, 51). Future 
studies should aim at discriminating injected cells 
from endogenous ones by making use of cells with 
bioluminescence/fluorescence or by revealing specific 
epitopes for instance for cells of human origin. We did 
not see any elimination of AuNPs during the course of 
the study, which demonstrates the feasibility of 
long-term tracking but may also bring up a safety 
concern. It would be interesting to conduct a 
longitudinal imaging study over longer periods of 
time to define the time course (and pathways) of gold 
elimination from the brain. 
One limitation of X-ray based techniques for 
cellular imaging is their intrinsic low sensitivity. 
Nevertheless, it is interesting to note that the detection 
limit of SPCCT imaging was of the same order of 
magnitude as that of 19F MRI (i.e. 103-104 cells per 
voxel). This initial study used conventional recon-
struction by filtered back-projection therefore there is 
scope for improvement of sensitivity, for example by 
implementation of iterative reconstruction (52, 53). In 
addition, AuNP load per cell may be further 
optimized (54). In our study, the detection limits have 
been basically determined for informative purposes 
and should be investigated more thoroughly as a next 
step. However, the main difficulty is the need for a 
gold standard technique that would allow precise 
evaluation of the gold amount in a given voxel. To 
address this issue, most brains of the current study 
have been further imaged with in vivo K-edge imaging 
and ex vivo phase-contrast imaging using X-rays from 
Synchrotron radiations (data analysis is on-going and 
will be published elsewhere). Another limitation of 
SPCCT for cell tracking may be patient exposure to 




ionizing radiations. Radiotoxicity is not an issue for 
longitudinal follow-up of rodents with µCT (55, 56). 
In the same way, SPCCT may allow safe, multiple 
exams of the same patient since the scans are 
performed at a much lower dose when compared to 
conventional CT for an equivalent image quality and 
also because of the elimination for the need of prescan 
(14, 48, 57-60).  
The SPCCT prototype that we have used for this 
study displayed all the characteristics of a clinical CT 
scanner, but a reduced field of view (28). Due to 
improved image quality compared to conventional 
CT, we were able to image rats and mice brains with 
sufficient details to track therapeutic cells. SPCCT 
clinical scanners with full field of view are now 
available (61), including in our own institution. 
Therefore, there is hope that the SPCCT approach that 
we propose may help investigations of cell therapy 
and ATMP combinations in future clinical trials. Some 
hurdles, however, need to be overcome in the 
preclinical field beforehand. The main questions arise 
from the fate of contrast agents in the body (e.g. 
potential accumulation in the brain) and the possible 
interactions between the contrast agents and the 
therapeutic effects. It would be too long to debate 
these issues here, but two points might be interesting 
to consider with regard to the use of gold as the cell 
label. First, it has been shown recently that 
macrophages were able to scavenge AuNPs and 
eliminate them through exosomes (62). Second, 
previous studies have shown that macrophage 
function was not affected by gold loading (29, 63). Of 
course, these issues should be addressed in 
well-designed in vitro and in vivo experiments. We 
believe that our results represent a major milestone 
from a methodological point of view and should 
facilitate better characterization and optimization of 
cell therapies at the preclinical level. In the present 
study, rats were not submitted to stroke because our 
main purpose was to evaluate a novel imaging 
approach; thus a ‘morphological’ and ‘radiological’ 
model of brain lesion that did not induce mortality. 
One of the perspectives of our work is to evaluate the 
effects of the intracerebral administration of 
therapeutic cells aimed at modulating neuroinflam-
mation (such as M2-polarized macrophages or human 
mesenchymal stem cells) in a rat model of ischemic 
stroke by coupling multimodal imaging (SPCCT for 
monitoring cells and scaffold and advanced 
multiparametric MRI methods for evaluating tissue 
repair) with neurobehavior and immunohisto-
chemistry analyses. Because of its translational nature, 
this protocol may help bridging the gap between 
preclinical and clinical trials, and thus foster the 
future approval of efficient cell therapies and ATMP 
combinations for stroke patients.  
Conclusions 
Multicolor CT is an innovative translational 
imaging tool that allows monitoring and quantifying 
therapeutic cells and their encapsulating scaffold 
transplanted into the damaged rat brain. 
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